2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002

Vasogen To Present at Adams Harkness' 25th Annual Summer Seminar

Toronto, Ontario - July 27, 2005

Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a leader in the research and commercial development of technologies targeting chronic inflammation underlying cardiovascular and neurological disease, today announced that its President and Chief Executive Officer, David Elsley, will present a Company overview at the Adams Harkness’ 25th Annual Summer Seminar at the Boston Marriott Long Wharf Hotel, at 4:30 p.m. Eastern Time on Tuesday, August 2, 2005, in Boston.

A live audio web cast of the presentation can be accessed through Vasogen’s web site at: www.vasogen.com. An archived replay will be available following the presentation.

About Vasogen
Vasogen is focused on the research and commercial development of technologies targeting the chronic inflammation underlying cardiovascular and neurological disease. The Company’s lead product, the Celacade™ technology, is currently in two pivotal phase III clinical trials designed to support regulatory approval in North America and commercialization in North America and Europe. The pivotal phase III SIMPADICO trial, which is fully enrolled at 50 centers in North America, is designed to further investigate the use of Celacade technology to improve intermittent claudication, a debilitating symptom associated with peripheral arterial disease. The pivotal phase III ACCLAIM trial, designed to further investigate the use of Celacade technology to reduce the risk of death and hospitalization in patients with advanced chronic heart failure, is fully enrolled at 176 clinical centers in North America, Europe, and Israel. Vasogen is also developing a new class of drugs for the treatment of neuro-inflammatory disorders, such as Alzheimer’s disease. VP025, which has completed phase I clinical development, is the lead product candidate from this new class of drugs.